Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.
about
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis CHealth state utilities associated with attributes of treatments for hepatitis C.Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortalityDaclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.Management of HCV in cirrhosis-a rapidly evolving landscape.Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
P2860
Q33853210-4D36EA35-2A83-42C1-8D01-7D0B05D166D7Q34271143-22BD4DD2-1D5B-4A17-9705-3279BF35F895Q35522668-0D143C28-6DB3-4DDB-B72A-B20505443D1BQ36285092-88AC81A7-122B-4317-8EF7-F27F21B274A8Q37066393-C50CEE79-F418-459C-939F-E4F066C46AACQ38198618-A80DF6A4-FCEC-438C-B1B0-363C55C07862Q38398290-E6C9BE50-4E42-47A2-8F31-893D0E541C51Q38432047-DBCA5769-5956-4398-82C0-7CBA5B313919Q38689820-B7FB7E6D-D3FF-411D-86B6-E6946657A3F9Q40579878-A238785A-4635-4ED4-911B-C2DD3FDDADCDQ41923104-873A7244-B6C6-4EE4-BC13-69F57CBCE140Q42244565-92C1D737-D4CA-4647-9B20-CA8712A0E5E5Q44666957-57BCABA3-1137-4C29-957C-4A1A0010A425
P2860
Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Severe adverse events during a ...... patients: A systematic review.
@ast
Severe adverse events during a ...... patients: A systematic review.
@en
type
label
Severe adverse events during a ...... patients: A systematic review.
@ast
Severe adverse events during a ...... patients: A systematic review.
@en
prefLabel
Severe adverse events during a ...... patients: A systematic review.
@ast
Severe adverse events during a ...... patients: A systematic review.
@en
P2093
P2860
P356
P1476
Severe adverse events during a ...... patients: A systematic review.
@en
P2093
Adriana Maria Neghină
Alina Popescu
Ioan Sporea
Mihnea Străin
Mirela Dănilă
Simona Bota
P2860
P304
P356
10.4254/WJH.V5.I3.120
P50
P577
2013-03-01T00:00:00Z